MedDataX Logo

Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism

NCT ID: NCT02017743

Last Updated: 2013-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter post authorization observational study. Cancer patients diagnosed with non high risk VTE and are followed up in an outpatient setting will be treated with LMWH and the data will be recorded. Since this is an observational study there are no specific treatment protocols, i.e., patients will be treated according to the best investigator's criteria. Treatment protocol will be based on the routine treatment practice of the involved investigator. Patients to enroll will be cancer patients diagnosed for VTE and who are able to receive outpatient LMWH treatment. There will be no specific hypothesis to be tested.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Inclusion criteria

* 18 years or upper age
* A signed informed consent document
* Cancer patient diagnosed for VTE
* Life expectancy \> 6 months
* Eligible for criteria of outpatient administration of LMWH

Exclusion criteria

• Should not carry any medical situation listed below, that outpatient administration of LMWH might be risky :

1. Patients with active bleeding or at-risk for bleeding
2. Major surgery in the last 7 days
3. Cardiopulmonary unstability
4. Severe systemic venous occlusion
5. Patients at high risk for pulmonary embolism
6. Thrombocytopenia (\<50000/microliter)
7. Inpatients under medical or surgery supervision
8. Patients with low ability to communicate and for whom it is not possible to provide care at home
9. INR≥1.5 due to liver functions impairment
10. Diagnosed for cerebral vascular aneurism
11. Active gastric and/or duodenum ulcer
12. Diagnosed for bacterial endocarditis
13. Severe renal function impairment (Creatinine clearance \< 30 ml/min)
14. Grade 3 hypertension (DBP \>= 110 mmHg and/or SBP \>= 180 mmHg)
15. \<35 kg or ≥110 kg weight
16. Known allergy to heparin and/or its derivatives
17. History of cerebrovascular event in the last 1 month
18. Active haemorrhage within the last 3 months

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or upper age
* A signed informed consent document
* Cancer patient diagnosed for VTE
* Life expectancy \> 6 months
* Eligible for criteria of outpatient administration of LMWH

Exclusion Criteria

* Patients with active bleeding or at-risk for bleeding
* Major surgery in the last 7 days
* Cardiopulmonary unstability
* Severe systemic venous occlusion
* Patients at high risk for pulmonary embolism
* Thrombocytopenia (\<50000/microliter)
* Inpatients under medical or surgery supervision
* Patients with low ability to communicate and for whom it is not possible to provide care at home
* INR≥1.5 due to liver functions impairment
* Diagnosed for cerebral vascular aneurism
* Active gastric and/or duodenum ulcer
* Diagnosed for bacterial endocarditis
* Severe renal function impairment (Creatinine clearance \< 30 ml/min)
* Grade 3 hypertension (DBP \>= 110 mmHg and/or SBP \>= 180 mmHg)
* \<35 kg or ≥110 kg weight
* Known allergy to heparin and/or its derivatives
* History of cerebrovascular event in the last 1 month
* Active haemorrhage within the last 3 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Trio Grup Clinical Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Metin Ozkan, Prof.

Role: PRINCIPAL_INVESTIGATOR

Erciyes University Faculty of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Erciyes University Faculty of Medicine

Kayseri, Melikgazi, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Metin Ozkan, Prof

Role: CONTACT

Email: [email protected]

Ilker Kurkcu, Pharm

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Metin Ozkan, Prof

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TREBECA

Identifier Type: -

Identifier Source: org_study_id